logo-loader

CBD maker Isodiol sees shares hit new high after fiscal 1Q revenue more than triples

Last updated: 13:10 12 Sep 2018 EDT, First published: 11:14 12 Sep 2018 EDT

cannabidiol (CBD) oil in a vial
Isodiol manufactures and develops cannabidiol (CBD) consumer products

Isodiol International Inc (CSE:ISOL, OTCQB:ISOLF) released robust quarterly earnings late Tuesday that sent its shares soaring in New York.

The company said first-quarter revenue was C$9.2mln, a 240% increase over the quarter ended June 30, 2017, and 70% better than revenue of C$5.4mln seen in the fourth quarter of fiscal 2018.

With a cash position of C$11.5mln, the company is "proud to report another significant increase in its revenues," said chief executive Marcos Agramont.

Shares added 40% to an all-time high of US$3.03 on Wednesday. Isodiol manufactures and develops cannabidiol (CBD) consumer products.

READ: Auxly Cannabis shares rocket as it advances $4mln to Lotus Ventures to complete growing facility

"With regulation in the United States seemingly trending towards a favourable position, the company believes it is well positioned to capitalize on upcoming opportunities with a variety of distribution channels," said Agramont. "As we head towards the end of fiscal quarter two and beyond, the company will continue to focus on building its three core business strategies: nutraceutical, pharmaceutical, and clinical supply of CBD Ingredients, contract manufacturing of consumer products containing CBD ingredients, and total vertical Integration of key revenue streams."

In May, Isodiol completed its acquisition of KURE Corp, which specializes in the retailing of vaporizers and e-cigarettes, e-juices, and related accessories.

Isodiol has also signed a binding agreement to acquire 51% of Farmtiva, a cultivator of hemp with operations in California.

It also signed an agreement to acquire 51% of Round Mountain Technologies, a cultivator of hemp with operations in Nevada.

--Updates share price--

Xeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for...

Xeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share news the company had a successful 2023, with a final tally of 164 million USD, which is at the upper end of their forecast. The company concluded the year with 72 million USD in cash, surpassing their initial projections...

11 hours, 23 minutes ago